



CENTER FOR
DATA INSIGHTS
AND INNOVATION
CALIFORNIA HEALTH &
HUMAN SERVICES AGENCY

2023-24 Edition Health Care Quality Report Cards Summary of Changes

This document summarizes key changes to the upcoming 2023-24 Edition Health Care Quality Report Cards, which include data from Measurement Year (MY) 2022.

Health Plan Report Card – 2023-24 Edition

Below are the updates to the Health Plan Report Card methodologies for MY 2022:

1. EPO Reporting Type:

- A. Historically, CDII/OPA has used HMO, POS, PPO, or any combination thereof for the benchmark calculation. However, CDII/OPA has not included EPO or any combinations involving EPO for the CDII/OPA national benchmark until this update for MY 2022. EPO is now included as a plan type in the calculation to provide a more accurate national benchmark.

This change in plan reporting type applies to both Healthcare Effectiveness Data and Information Set (HEDIS®¹) and Consumer Assessment of Healthcare Providers and Systems (CAHPS®²).

2. Various HEDIS measure updates were made for MY 2022:

A. Comprehensive Diabetes Care (CDC):

- i. The CDC measure was retired for MY 2022; however, some indicators were developed into stand-alone measures listed below:
- a. “Eye Exam for People with Diabetes” is now under code EED (“Eye Exam for Patients with Diabetes”).
 - b. “Controlling Blood Pressure for People with Diabetes” is now under code BPD (“Blood Pressure Control for Patients with Diabetes”).
 - c. “Controlling Blood Sugar for People with Diabetes” is now under code HBD (“Hemoglobin A1c Control for Patients with Diabetes – HbA1c Control (<8%)”).
- ii. “Testing Blood Sugar for People with Diabetes” is no longer in use for MY 2022, as the HbA1c Testing HEDIS Indicator has been retired.

B. Colorectal Cancer Screening (COL):

- i. The age range in the denominator has expanded to 45 – 75 years of age (as opposed to the previous range of 51 – 75 years of age in MY 2021). To align with this change, the “Colorectal Cancer Screening (Total)” indicator will be utilized instead of using “Colorectal Cancer Screening (46-49)” and “Colorectal Cancer Screening (50-75)” separately.

C. Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET):

- i. The measure was heavily revised for MY 2022. The measure now includes the following indicators and age stratifications:

- a. Alcohol Use Disorder

- Initiation of SUD Treatment – Alcohol Use Disorder
- Engagement of SUD Treatment – Alcohol Use Disorder

- b. Opioid Use Disorder

- Initiation of SUD Treatment – Opioid Use Disorder
- Engagement of SUD Treatment – Opioid Use Disorder

- c. Other Drug Use Disorder

- Initiation of SUD Treatment – Other Drug Use Disorder
- Engagement of SUD Treatment – Other Drug Use Disorder

- d. Total

- Initiation of SUD Treatment – Total
- Engagement of SUD Treatment – Total

- e. Age Stratifications (for each indicator):

- 13 – 17 years old
- 18 – 64 years old
- 65+ years old
- Total

- ii. Instead of using the separate Alcohol Use Disorder, Opioid Use Disorder, Other Drug Use Disorder, and Total indicators and age stratifications listed above, CDII/OPA has chosen to utilize the following indicators for MY 2022:

- a. “Initiation and Engagement of Substance Use Disorder Treatment – Initiation of SUD Treatment – Total (Total)”

- b. “Initiation and Engagement of Substance Use Disorder Treatment – Engagement of SUD Treatment – Total (Total)”

D. Use of Imaging Studies for Low Back Pain (LBP):

- i. The age range for the denominator was expanded to 18 – 75 years of age (previously 18 – 50 years old).
- ii. While there are age stratifications available, CDII/OPA has chosen to utilize “Use of Imaging Studies for Low Back Pain (Total)” to capture the full age range.

¹ HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). HEDIS is a source for data contained in the California Health Care Quality Report Cards obtained from Quality Compass®2023 and is used with the permission of the National Committee for Quality Assurance (NCQA). Quality Compass 2023 includes certain CAHPS data. Any data display, analysis, interpretation, or conclusion based on these data is solely that of the authors, and NCQA specifically disclaims responsibility for any such display, analysis, interpretation, or conclusion. Quality Compass is a registered trademark of NCQA.

² CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).